[go: up one dir, main page]

WO2007111940A3 - Regimens for immunisation with meningococcal conjugates - Google Patents

Regimens for immunisation with meningococcal conjugates Download PDF

Info

Publication number
WO2007111940A3
WO2007111940A3 PCT/US2007/007115 US2007007115W WO2007111940A3 WO 2007111940 A3 WO2007111940 A3 WO 2007111940A3 US 2007007115 W US2007007115 W US 2007007115W WO 2007111940 A3 WO2007111940 A3 WO 2007111940A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunisation
regimens
meningococcal conjugates
administered
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/007115
Other languages
French (fr)
Other versions
WO2007111940A2 (en
Inventor
Lisa Danzig
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38327015&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007111940(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2007229449A priority Critical patent/AU2007229449A1/en
Priority to US12/225,501 priority patent/US10543265B2/en
Priority to CA2646993A priority patent/CA2646993C/en
Priority to ES07753720T priority patent/ES2383209T3/en
Priority to DK07753720.7T priority patent/DK2004225T3/en
Priority to SI200730954T priority patent/SI2004225T1/en
Priority to PL07753720T priority patent/PL2004225T3/en
Application filed by Novartis AG filed Critical Novartis AG
Priority to NZ572054A priority patent/NZ572054A/en
Priority to AT07753720T priority patent/ATE554788T1/en
Priority to EP07753720A priority patent/EP2004225B1/en
Publication of WO2007111940A2 publication Critical patent/WO2007111940A2/en
Publication of WO2007111940A3 publication Critical patent/WO2007111940A3/en
Anticipated expiration legal-status Critical
Priority to US12/287,225 priority patent/US10828361B2/en
Priority to US16/716,638 priority patent/US10881721B2/en
Priority to US17/082,415 priority patent/US20210060151A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/36—Neisseria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Multivalent meningococcal conjugate vaccines are administered according to a schedule in which a first dose is administered to a patient aged between 0 and 12 months, and a second dose is administered to the patient aged between 12 and 24 months.
PCT/US2007/007115 2006-03-22 2007-03-22 Regimens for immunisation with meningococcal conjugates Ceased WO2007111940A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AT07753720T ATE554788T1 (en) 2006-03-22 2007-03-22 SCHEMATICS FOR IMMUNIZATION WITH MENINGOCOCCAL CONJUGATES
NZ572054A NZ572054A (en) 2006-03-22 2007-03-22 Regimens for immunisation with meningococcal conjugates
CA2646993A CA2646993C (en) 2006-03-22 2007-03-22 Regimens for immunisation with meningococcal conjugates
ES07753720T ES2383209T3 (en) 2006-03-22 2007-03-22 Regimens for immunization with meningococcal conjugates
DK07753720.7T DK2004225T3 (en) 2006-03-22 2007-03-22 Programs for vaccination with meningococcal conjugates
SI200730954T SI2004225T1 (en) 2006-03-22 2007-03-22 Regimens for immunisation with meningococcal conjugates
PL07753720T PL2004225T3 (en) 2006-03-22 2007-03-22 Regimens for immunisation with meningococcal conjugates
AU2007229449A AU2007229449A1 (en) 2006-03-22 2007-03-22 Regimens for immunisation with meningococcal conjugates
US12/225,501 US10543265B2 (en) 2006-03-22 2007-03-22 Regimens for immunisation with meningococcal conjugates
EP07753720A EP2004225B1 (en) 2006-03-22 2007-03-22 Regimens for immunisation with meningococcal conjugates
US12/287,225 US10828361B2 (en) 2006-03-22 2008-10-06 Regimens for immunisation with meningococcal conjugates
US16/716,638 US10881721B2 (en) 2006-03-22 2019-12-17 Regimens for immunisation with meningococcal conjugates
US17/082,415 US20210060151A1 (en) 2006-03-22 2020-10-28 Regimens for immunisation with meningococcal conjugates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78523406P 2006-03-22 2006-03-22
US60/785,234 2006-03-22

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US12/225,501 A-371-Of-International US10543265B2 (en) 2006-03-22 2007-03-22 Regimens for immunisation with meningococcal conjugates
US12/287,225 Continuation-In-Part US10828361B2 (en) 2006-03-22 2008-10-06 Regimens for immunisation with meningococcal conjugates
US16/716,638 Continuation US10881721B2 (en) 2006-03-22 2019-12-17 Regimens for immunisation with meningococcal conjugates

Publications (2)

Publication Number Publication Date
WO2007111940A2 WO2007111940A2 (en) 2007-10-04
WO2007111940A3 true WO2007111940A3 (en) 2007-11-15

Family

ID=38327015

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/007115 Ceased WO2007111940A2 (en) 2006-03-22 2007-03-22 Regimens for immunisation with meningococcal conjugates

Country Status (14)

Country Link
US (4) US10543265B2 (en)
EP (2) EP2357001B1 (en)
AT (1) ATE554788T1 (en)
AU (1) AU2007229449A1 (en)
CA (1) CA2646993C (en)
CY (1) CY1112920T1 (en)
DK (1) DK2004225T3 (en)
ES (2) ES2670231T3 (en)
NZ (1) NZ572054A (en)
PL (1) PL2004225T3 (en)
PT (1) PT2004225E (en)
SI (1) SI2004225T1 (en)
TR (1) TR201807355T4 (en)
WO (1) WO2007111940A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60144353D1 (en) 2000-02-28 2011-05-12 Novartis Vaccines & Diagnostic Hybrid Expression of Neisserscher Proteins
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
MX339524B (en) 2001-10-11 2016-05-30 Wyeth Corp NEW IMMUNOGENIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF MENINGOCOCICAL DISEASE.
ES2411080T3 (en) * 2003-01-30 2013-07-04 Novartis Ag Injectable vaccines against multiple serogroups of meningococci
ES2670231T3 (en) * 2006-03-22 2018-05-29 Glaxosmithkline Biologicals S.A. Regimens for immunization with meningococcal conjugates
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
AR064642A1 (en) 2006-12-22 2009-04-15 Wyeth Corp POLINUCLEOTIDE VECTOR THAT INCLUDES IT RECOMBINATING CELL THAT UNDERSTANDS THE VECTOR POLYPEPTIDE, ANTIBODY, COMPOSITION THAT UNDERSTANDS THE POLINUCLEOTIDE, VECTOR, RECOMBINATING CELL POLYPEPTIDE OR ANTIBODY, USE OF THE COMPOSITION AND A COMPOSITION AND A METHOD
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
NZ595291A (en) * 2009-03-24 2013-08-30 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
SI3831406T1 (en) 2010-08-23 2024-08-30 Wyeth Llc Stable formulations of neisseria meningitidis rlp2086 antigens
NZ607224A (en) 2010-09-10 2014-11-28 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
SA115360586B1 (en) 2012-03-09 2017-04-12 فايزر انك Neisseria meningitidis compositions and methods thereof
RU2665841C2 (en) 2012-03-09 2018-09-04 Пфайзер Инк. Neisseria meningitidis compositions and methods of use thereof
EP2964665B1 (en) 2013-03-08 2018-08-01 Pfizer Inc Immunogenic fusion polypeptides
JP6747968B2 (en) 2013-03-18 2020-08-26 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Method of treatment
BR112016004463A2 (en) 2013-09-08 2017-10-17 Pfizer neisseria meningitidis compositions and methods thereof
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
CN104998255B (en) * 2015-06-30 2018-08-28 北京祥瑞生物制品有限公司 New A CYW135 group meningitis cocci combined vaccines and preparation method thereof
LT3506935T (en) 2016-09-02 2024-04-25 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine
CN118021947A (en) 2017-01-31 2024-05-14 辉瑞大药厂 Neisseria meningitidis compositions and methods of use thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
MX2022003682A (en) 2019-09-27 2022-04-25 Pfizer COMPOSITIONS OF NEISSERIA MENINGITIDIS AND METHODS THEREOF.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531131B1 (en) * 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
US20030068336A1 (en) * 2001-01-23 2003-04-10 Ryall Robert P. Multivalent meningococcal polysaccharide-protein conjugate vaccine
WO2005000345A2 (en) * 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
IT1187753B (en) 1985-07-05 1987-12-23 Sclavo Spa GLYCOPROTEIC CONJUGATES WITH TRIVALENT IMMUNOGENIC ACTIVITY
NL8802046A (en) 1988-08-18 1990-03-16 Gen Electric POLYMER MIXTURE WITH POLYESTER AND ALKANE SULFONATE, OBJECTS THEREFORE.
DE3841091A1 (en) 1988-12-07 1990-06-13 Behringwerke Ag SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE
ES2055785T3 (en) 1989-01-17 1994-09-01 Eniricerche Spa SYNTHETIC PEPTIDES AND THEIR USE AS UNIVERSAL VEHICLES FOR THE PREPARATION OF IMMUNOGENOUS CONJUGATES SUITABLE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
FI920131A0 (en) 1989-07-14 1992-01-13 Praxis Biolog Inc CYTOKIN- OCH HORMONBAERARE FOER KJJUGATVACCIN.
IT1237764B (en) 1989-11-10 1993-06-17 Eniricerche Spa SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES.
SE466259B (en) 1990-05-31 1992-01-20 Arne Forsgren PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE
DE69113564T2 (en) 1990-08-13 1996-05-30 American Cyanamid Co Bordetella pertussis fiber hemagglutinin as a carrier for conjugated vaccine.
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
WO1992016232A1 (en) 1991-03-12 1992-10-01 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce Polysaccharide-protein conjugates
IT1262896B (en) 1992-03-06 1996-07-22 CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES.
ATE188508T1 (en) 1992-06-18 2000-01-15 Harvard College VACCINES AGAINST DIPHTHERIAL TOXIN
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
ES2171418T3 (en) 1992-08-31 2002-09-16 Baxter Healthcare Sa VACCINES AGAINST NEISSERIA MENINGITIDIS OF GROUP C.
US5425946A (en) 1992-08-31 1995-06-20 North American Vaccine, Inc. Vaccines against group C Neisseria meningitidis
NZ274376A (en) 1993-09-22 1997-11-24 Jackson H M Found Military Med Activating soluble carbohydrate using cyanylating reagents for the production of immunogenic constructs
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
ATE400295T1 (en) 1995-06-07 2008-07-15 Glaxosmithkline Biolog Sa VACCINE WITH A POLYSACCHARIDE ANTIGEN CARRIER PROTEIN CONJUGATE AND FREE CARRIER PROTEIN
US5811102A (en) * 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
DE69612198T3 (en) 1995-06-23 2011-08-18 Smithkline Beecham Biologicals S.A. A vaccine composition consisting of a Haemophilus influenzae B polysaccharide antigen conjugate adsorbed to aluminum phosphate
US6248334B1 (en) 1997-01-08 2001-06-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Process for preparing conjugate vaccines including free protein and the conjugate vaccines, immunogens, and immunogenic reagents produced by this process
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US6403306B1 (en) 1997-04-09 2002-06-11 Emory University Serogroup-specific nucleotide sequences in the molecular typing of bacterial isolates and the preparation of vaccines thereto
EP0977588B1 (en) 1997-04-24 2004-10-06 Henry M. Jackson Foundation For The Advancement Of Military Medicine Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
WO1998058670A1 (en) 1997-06-24 1998-12-30 Chiron Corporation Methods of immunizing adults using anti-meningococcal vaccine compositions
US5965714A (en) 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
CZ302615B6 (en) 1997-12-23 2011-08-03 Baxter Healthcare S.A. Method of purifying capsular polysaccharides from cellular components of gram-negative and gram-positive bacteria and modified capsular polysaccharide per se
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
CN1263510C (en) 1998-08-19 2006-07-12 巴克斯特健康护理股份有限公司 Polysaccharide-protein conjugate or oligosaccharide-protein conjugate, preparation method and application thereof
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
IL145043A0 (en) 1999-03-19 2002-06-30 Smithkline Beecham Biolog Vaccine
JP2002541808A (en) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド Recombinant toxin A protein carrier for polysaccharide conjugate vaccine
GB9925559D0 (en) 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
JP4948731B2 (en) 1999-12-02 2012-06-06 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Compositions and methods for stabilizing biological molecules during lyophilization
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
HU227893B1 (en) 2000-06-29 2012-05-29 Glaxosmithkline Biolog Sa Vaccine compositions
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CA2480389C (en) 2002-03-26 2012-10-09 Chiron Srl Modified saccharides having improved stability in water
DE60328481D1 (en) 2002-05-14 2009-09-03 Novartis Vaccines & Diagnostic SLEEP-CAPACITIVE VACCINE CONTAINING THE ADJUVANZ CHITOSAN AND MENIGOKOKKENANTIGENE
ES2411080T3 (en) 2003-01-30 2013-07-04 Novartis Ag Injectable vaccines against multiple serogroups of meningococci
EP1624888B1 (en) * 2003-05-07 2016-10-12 Sanofi Pasteur, Inc. Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccine
BRPI0411815A (en) * 2003-06-23 2006-08-08 Baxter Int y-type neisseria meningitidis vaccines and their meningococcal combinations
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
EP2272531A3 (en) 2004-04-30 2011-04-13 Novartis Vaccines and Diagnostics S.r.l. Integration of meningococcal conjugate vaccination
EP1784214A4 (en) 2004-08-30 2009-09-23 Sanofi Pasteur Inc Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
GB0419627D0 (en) * 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
KR20130122810A (en) * 2005-06-27 2013-11-08 글락소스미스클라인 바이오로지칼즈 에스.에이. Process for manufacturing vaccines
BRPI0615420A2 (en) 2005-09-01 2011-05-17 Novartis Vaccines & Diagnostic multiple vaccination including serogroup c meningococcus
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
ES2670231T3 (en) * 2006-03-22 2018-05-29 Glaxosmithkline Biologicals S.A. Regimens for immunization with meningococcal conjugates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6531131B1 (en) * 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
US20030068336A1 (en) * 2001-01-23 2003-04-10 Ryall Robert P. Multivalent meningococcal polysaccharide-protein conjugate vaccine
WO2005000345A2 (en) * 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BORROW RAY ET AL: "Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United Kingdom.", INFECTION AND IMMUNITY, vol. 71, no. 10, October 2003 (2003-10-01), pages 5549 - 5555, XP002446851, ISSN: 0019-9567 *
LEACH AMANDA ET AL: "Induction of immunologic memory in Gambian children by vaccination in infancy with a group A plus group C meningococcal polysaccharide-protein conjugate vaccine", JOURNAL OF INFECTIOUS DISEASES, vol. 175, no. 1, 1997, pages 200 - 204, XP008082381, ISSN: 0022-1899 *

Also Published As

Publication number Publication date
EP2004225B1 (en) 2012-04-25
PT2004225E (en) 2012-05-30
PL2004225T3 (en) 2012-09-28
CA2646993A1 (en) 2007-10-04
ES2383209T3 (en) 2012-06-19
NZ572054A (en) 2011-12-22
US20090297553A1 (en) 2009-12-03
CY1112920T1 (en) 2016-04-13
CA2646993C (en) 2016-01-26
US20200138932A1 (en) 2020-05-07
SI2004225T1 (en) 2012-08-31
US10881721B2 (en) 2021-01-05
EP2357001B1 (en) 2018-03-07
DK2004225T3 (en) 2012-08-06
EP2004225A2 (en) 2008-12-24
US10543265B2 (en) 2020-01-28
ES2670231T3 (en) 2018-05-29
ATE554788T1 (en) 2012-05-15
EP2357001A1 (en) 2011-08-17
US20210060151A1 (en) 2021-03-04
US20080026002A1 (en) 2008-01-31
TR201807355T4 (en) 2018-06-21
WO2007111940A2 (en) 2007-10-04
AU2007229449A1 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
WO2007111940A3 (en) Regimens for immunisation with meningococcal conjugates
WO2007071786A3 (en) Conjugate vaccines
IL222346A (en) Immunogenic composition comprising at least two different n meningitides capsular saccharides, uses thereof and a vaccine comprising the same
CY1110140T1 (en) Vaccination with Miningococcal conjugate
NZ598367A (en) Multiple vaccination including serogroup C meningococcus
AR080122A1 (en) COMPOSITION OF CONJUGATED VACCINE OF POLISACARIDO-PROTEIN NEUMOCOCICA 15-VALENTE
WO2007116028A3 (en) Conjugate vaccines
WO2005105140A3 (en) Meningococcal conjugate vaccination
AR058592A1 (en) VACCINE
WO2008021076A3 (en) Protein matrix vaccines and methods of making and administering such vaccines
WO2005105141A3 (en) Combined meningococcal conjugates with common carrier protein
WO2010067202A3 (en) Mixing lyophilised meningococcal vaccines with non-hib vaccines
WO2007142810A3 (en) Methods of using low-dose doxepin for the improvement of sleep
EP2364725A3 (en) Immunization method against neisseria meningitidis serogroups a and c
IL181951A0 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
WO2009143413A8 (en) Synergistic immunogenic fusion protein-polysaccharide conjugate
ZA200701675B (en) Multivalent meningococcal derivatized polysaccharideprotein conjugates and vaccine
WO2007083190A3 (en) Water insoluble helichrysum extract, process for preparing the same and uses thereof
MX382165B (en) Method of treatment
WO2005072704A3 (en) Method of treating acute rhinosinusitis
WO2009108168A3 (en) Gold nanoparticle glycoconjugates for generating igg specific for the carbohydrate
HK1064682A (en) Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07753720

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2646993

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007229449

Country of ref document: AU

Ref document number: 572054

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2007753720

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2007229449

Country of ref document: AU

Date of ref document: 20070322

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12225501

Country of ref document: US